3.6 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | Phase 2 RCT Protocol: Semaglutide for OUD Abstinence in Treatment-Refractory Patients (Grigson/Penn State, NCT06548490) | Grigson PS et al. / Penn State / Addiction Science & Clinical Practice | https://pmc.ncbi.nlm.nih.gov/articles/PMC12154142/ | 2025 | health | peer-reviewed study | unprocessed | medium |
|
Content
Protocol publication for a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating semaglutide for opioid use disorder.
Trial registration: NCT06548490
Design:
- 200 participants with treatment-refractory OUD
- Outpatient population already receiving standard MOUD (buprenorphine or methadone)
- Three sites (NIH-funded)
- 12-week treatment period
- Double-blind, placebo-controlled
Primary endpoint: Opioid abstinence (confirmed by urine drug screens + self-report)
Background:
- Rodent models: GLP-1 RAs reduce opioid self-administration
- Residential OUD population: GLP-1 RAs decrease craving measures
- No completed controlled trial for outpatient OUD as of protocol publication (2025)
- Real-world data (Qeadan 2025): 40% lower opioid overdose rate in GLP-1 RA users
Concerns noted:
- Side effects: pancreatic cysts, pancreatic cancer risk, hypoglycemia, muscle cramps, cognitive slowing
- Adding GLP-1 to MOUD (buprenorphine/methadone) background — drug interaction considerations
- Population is treatment-refractory — higher difficulty achieving abstinence
Current status: Protocol published; trial ongoing; NO RESULTS AVAILABLE as of April 2026.
Agent Notes
Why this matters: This is the only active well-powered Phase 2 RCT for GLP-1 in OUD. Its results (expected 2026-2027) will determine whether the Qeadan 2025 real-world signal holds up under controlled conditions. If the trial shows significant opioid abstinence improvement, the GLP-1 reward circuit mechanism claim becomes "likely" confidence. If null, the mechanism may be specific to food/alcohol reward circuits.
What surprised me: The trial is specifically for TREATMENT-REFRACTORY patients — those who are not achieving abstinence with buprenorphine or methadone. This is a high-need, hard-to-treat population. A positive result here would be especially meaningful.
What I expected but didn't find: Results. This is protocol-only.
KB connections:
- The pending results will directly inform whether the GLP-1 reward circuit claim can extend to opioids (currently experimental based on Qeadan observational + animal models)
- Active monitoring thread — check for results Q3/Q4 2026 or early 2027
Extraction hints:
- Do NOT extract as a claim — this is protocol only
- Archive as a monitoring item: "Phase 2 RCT underway, results expected 2026-2027"
- When results publish, this becomes a primary source for the OUD extension of the reward circuit claim
Context: Grigson is a leading addiction neuroscience researcher at Penn State. NIH-funded Phase 2 trial with OUD-focused design.
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: GLP-1 reward circuit mechanism claim — OUD extension (pending) WHY ARCHIVED: Protocol-only source. Monitor for results. This trial will resolve whether the GLP-1 mechanism extends to opioid abstinence in treatment-refractory patients. Do not extract now. EXTRACTION HINT: No extraction yet. Flag as monitoring item. Revisit when trial results publish (expected 2026-2027).